| Median follow-up time |
1176.5 days (3.2 y); SD: 809 days (2.2 y) |
1030.5 days (2.8 y); SD: 823 days (2.6 y) |
| Age (y), mean (SD) |
61.6 (12.7) |
62.5 (12.9) |
| Age group, n (%) |
| 18-34 |
39 (1.4) |
35 (2.3) |
| 35-44 |
184 (6.8) |
78 (5.1) |
| 45-54 |
551 (20.3) |
264 (17.4) |
| 55-64 |
922 (34.0) |
529 (34.8) |
| 65-74 |
548 (20.2) |
325 (21.4) |
| ≥75 |
468 (17.3) |
289 (19.0) |
| Gender, n (%) |
| Female |
1285 (47.4) |
736 (48.4) |
| Male |
1427 (52.6) |
784 (51.6) |
| Geographic region, n (%) |
| Northeast region |
451 (16.6) |
418 (27.5) |
| North central region |
897 (33.1) |
409 (26.9) |
| South region |
1008 (37.2) |
463 (30.5) |
| West region |
354 (13.1) |
228 (15.0) |
| Unknown region |
2 (0.1) |
2 (0.1) |
| Health plan, n (%) |
| Commercial |
1703 (62.8) |
918 (60.4) |
| Medicare |
1009 (37.2) |
602 (39.6) |
| Year of diagnosis, n (%) |
| 2008 |
69 (2.5) |
29 (1.9) |
| 2009 |
151 (5.6) |
102 (6.7) |
| 2010 |
169 (6.2) |
75 (4.9) |
| 2011 |
204 (7.5) |
83 (5.5) |
| 2012 |
298 (11.0) |
160 (10.5) |
| 2013 |
363 (13.4) |
196 (12.9) |
| 2014 |
478 (17.6) |
238 (15.7) |
| 2015 |
589 (21.7) |
373 (24.5) |
| 2016 |
391 (14.4) |
264 (17.4) |
| Baseline comorbidity, n (%) |
| Myocardial infarction |
50 (1.8) |
32 (2.1) |
| Congestive heart failure |
112 (4.1) |
83 (5.5) |
| Peripheral vascular disease |
199 (7.3) |
123 (8.1) |
| Cerebrovascular disease |
180 (6.6) |
114 (7.5) |
| Dementia |
7 (0.3) |
5 (0.3) |
| Chronic pulmonary disease |
416 (15.3) |
216 (14.2) |
| Connective tissue disease, rheumatic disease |
109 (4.0) |
39 (2.6) |
| Peptic ulcer disease |
41 (1.5) |
15 (1.0) |
| Mild liver disease |
218 (8.0) |
106 (7.0) |
| Diabetes without complications |
483 (17.8) |
264 (17.4) |
| Diabetes with complications |
96 (3.5) |
58 (3.8) |
| Paraplegia and hemiplegia |
7 (0.3) |
15 (1.0) |
| Renal disease |
137 (5.1) |
81 (5.3) |
| Cancer |
716 (26.4) |
407 (26.8) |
| Moderate or severe liver disease |
8 (0.3) |
4 (0.3) |
| Metastatic carcinoma |
1 (0.0) |
0 (0.0) |
